Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parabilis MedicinesPBLS -1.00%10 Cash-to-Debt is 0.47 as of Dec. 2025, which is 48% below its 10-year median of 0.90. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,397 Biotechnology companies, Parabilis Medicines ranks worse than 85.18% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Parabilis Medicines's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.47.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Parabilis Medicinescouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Parabilis Medicines's Cash-to-Debt or its related term are showing as below:
PBLS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.47 Med: 0.9 Max: 1.33
Current: 0.47
During the past 2 years, Parabilis Medicines's highest Cash to Debt Ratio was 1.33. The lowest was 0.47. And the median was 0.90.
PBLS's Cash-to-Debt is ranked worse than 85.18% of 1397
companies
in the Biotechnology industry
Industry Median: 6.72
vs PBLS: 0.47
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Parabilis Medicines Cash-to-Debt Related Terms
Parabilis Medicines Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Parabilis Medicines's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Parabilis Medicines Cash-to-Debt Chart
Parabilis Medicines Annual Data
Trend
Dec24
Dec25
Cash-to-Debt
1.33
0.47
Parabilis Medicines Semi-Annual Data
Dec24
Dec25
Cash-to-Debt
1.33
0.47
PBLS vs DYN, ACAD, EWTX: Cash-to-Debt Comparison
For the Biotechnology subindustry, Parabilis Medicines's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parabilis Medicines Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Parabilis Medicines's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Parabilis Medicines's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parabilis Medicines (PBLS) has a Cash-to-Debt of 0.47 as of Dec. 2025. This is 48% below median its historical median of 0.90. Over the past decade, Parabilis Medicines' Cash-to-Debt has ranged from 0.47 to 1.33. According to the industry distribution chart, Parabilis Medicines ranks #1190 out of 1397 companies in the Biotechnology industry, placing it in the top 85.2%.
Is Parabilis Medicines' Cash-to-Debt too high?
Parabilis Medicines' current Cash-to-Debt of 0.47 is 48% below median its 10-year median of 0.90. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 1.33. The Biotechnology industry median Cash-to-Debt is 6.72. Parabilis Medicines' value of 0.47 is 93% below this industry median. Based on the distribution chart, Parabilis Medicines ranks #1190 out of 1397 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Cash-to-Debt compare to DYN and ACAD?
According to the Biotechnology industry distribution chart, Parabilis Medicines ranks #1190 out of 1397 companies for Cash-to-Debt. This places Parabilis Medicines in the lower half of its industry. The industry median Cash-to-Debt is 6.72. Parabilis Medicines' value of 0.47 is 93% below this benchmark. Historically, Parabilis Medicines' own Cash-to-Debt has ranged from 0.47 to 1.33 over the past decade. While the company's 10-year median is 0.90 vs. the industry median of 6.72, Parabilis Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.72, based on 1,397 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parabilis Medicines's current Cash-to-Debt of 0.47 is 93% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parabilis Medicines's current Cash-to-Debt is 0.47, which is 48% below median its own 10-year median of 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Cash-to-Debt of 0.47. The current Cash-to-Debt is 0.47, which is 48% below median its 10-year median of 0.90 and 93% below the Biotechnology industry median of 6.72. Parabilis Medicines' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Cash-to-Debt is 0.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score
Get the complete analysis for PBLS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBLS has been successfully added to your 
